TXA in the EMS on the Helicopter and the Ambulance (TXASRZREGA)
Administration of Tranexamic Acid in the Preclinical Setting and Its Effect on Coagulation Parameters and Outcome in Multiple Trauma Patients and Isolated TBI in EMS (Schutz Und Rettung Zürich) and Helicopter Rescue(REGA).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Oliver M Theusinger, PD Dr med
- Email: oliver.theusinger@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Recruiting
- USZ
-
Contact:
- Oliver M Theusinger, PD Dr med
- Phone Number: +41442552710
- Email: oliver.theusinger@usz.ch
-
-
ZH
-
Zurich, ZH, Switzerland, 8091
- Recruiting
- University Hospital Zurich, Division of Anaesthesiology
-
Contact:
- Oliver M Theusinger, PD Dr med
- Email: oliver.theusinger@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- multiple trauma
- traumatic brain injury
Exclusion Criteria:
- pregnant
- < 18 years
- no TXA
- not speaking the german language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Tranexamic Acid
TXA administered to multiple trauma patients in the helicopter or ambulance
|
Coagulation Management / Efficiency
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tranexamic acid administered in the preclinical setting and its influence on coagulation parameters (laboratory and thromboelastometry)
Time Frame: 12 Months
|
TXA will be given to multiple trauma patients or patients with isolated TBI in the preclinical setting (n=50).
Before tranexamic acid is given, one tube of citrated blood is drawn.
Once patients arrive in the emergency room as second tube of citrated blood is drawn.
The two tubes will be used to perform rotational thromboelastometry (ROTEM) measurements and standard coagulation measurements (aPTT, PT, INR, Ouick's value, fibrinogen).
The coagulation parameters on scene will be compared to those in the emergency department to find out if coagulation is improved by this.
In a previously performed study, 50 patients got blood taken on scene and in the emergency room without receiving TXA.
In this study by Theusinger et al. it was shown that coagulation is impaired during this time period.(Theusinger
OM et al.
Anesth Analg.
2014 Dec 24.PMID: 25545751).
The population of this study will serve as control group for the actually performed study.
|
12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Oliver M. Theusinger, PD Dr med, USZ
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KEK-ZH-Nr. 2014-0069
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.